MedImmune has won an expert panel vote to expand the use of FluMist to children. In a nine to six vote the panel concluded the benefits of the nasal spray outweighed the risks in children 1 to 5 years old with no known respiratory problems. MedImmune, which has agreed to a takeover bid from AstraZeneca, has been working to expand the market as well as ease of use of FluMist, which proved a colossal bomb when it was first approved in 2003.
- here's the report [1] from CNN on MedImmune
ALSO: Shareholders of MedImmune have filed a class action lawsuit claiming that AstraZeneca's $15.6 billion deal is designed to benefit MedImmune's execs more than its shareholders. Report [2]
Related story:
MedImmune boosted by new data on FluMist Report [3]
Links:
[1] http://money.cnn.com/2007/05/16/news/companies/bc.medimmune.flumist.reut/?postversion=2007051617
[2] http://business.timesonline.co.uk/tol/business/industry_sectors/health/article1801017.ece
[3] http://www.fiercebiotech.com/story/medimmune-boosted-by-new-data-on-flumist/2007-02-16